Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 8, 2022

Primary Completion Date

October 3, 2025

Study Completion Date

October 3, 2025

Conditions
Muscular Dystrophy, Duchenne
Interventions
GENETIC

PF-06939926

All participants will receive a single dose of PF-06939926 on Day 1.

Trial Locations (13)

2145

The Children's Hospital at Westmead, Westmead

3052

The Royal Children's Hospital Melbourne, Parkville

6009

Perth Children's Hospital, Nedlands

19104

The Children's Hospital of Philadelphia, Philadelphia

19146

The Children's Hospital of Philadelphia, Philadelphia

32610

UF Health Shands Hospital, Gainesville

University of Florida, Gainesville

84108

CTSI Clinical Research Center, Salt Lake City

University of Utah Imaging and Neurosciences Center, Salt Lake City

84112

University of Utah Hospital & Clinics Investigational Drug Services, Salt Lake City

84113

Primary Children's Hospital, Salt Lake City

84132

University of Utah Clinical Neurosciences Center, Salt Lake City

University of Utah Hospital, Salt Lake City

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT05429372 - Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy | Biotech Hunter | Biotech Hunter